(Q38219489)

31 August 2017

title

Anti-diabetes therapy: safety considerations for patients with impaired kidney function (English)

1 reference

31 August 2017

Janet B McGill

1

1 reference

31 August 2017

language of work or name

English

0 references

publication date

1 May 2014

1 reference

31 August 2017

published in

Postgraduate Medicine

1 reference

31 August 2017

volume

126

1 reference

31 August 2017

issue

3

1 reference

31 August 2017

page(s)

161-171

1 reference

Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2765

Patient awareness of chronic kidney disease: trends and predictors

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2765

Prediction of creatinine clearance from serum creatinine

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2765

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2765

A new equation to estimate glomerular filtration rate

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2765

Estimating glomerular filtration rate from serum creatinine and cystatin C.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2765

Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2765

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2765

Insulin resistance in patients with chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2765

Insulin resistance and risk of chronic kidney disease in nondiabetic US adults

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2765

Chronic kidney disease, insulin resistance, and incident diabetes in older adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2765

Glycemic control in diabetic dialysis patients and the burnt-out diabetes phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2765

Frequency of hypoglycemia and its significance in chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2765

A predictive model for progression of chronic kidney disease to kidney failure

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2765

Use of metformin in the setting of mild-to-moderate renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2765

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2765

Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2765

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2765

Glucose control and vascular complications in veterans with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2765

Effect of a multifactorial intervention on mortality in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2765

Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2765

Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2765

Pharmacokinetics of nateglinide in renally impaired diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2765

The pharmacokinetics of pioglitazone in patients with impaired renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2765

Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2765

Effect of renal impairment on the pharmacokinetics of exenatide

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2765

Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2765

The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2765

Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2765

Efficacy of pioglitazone on type 2 diabetic patients with hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2765

Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2765

Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2765

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2765

The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2765

Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2765

Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2765

Inherited variation in vitamin D genes is associated with predisposition to autoimmune disease type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2765

Mild renal impairment and the efficacy and safety of liraglutide.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2765

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2765

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2765

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2765

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2765

21 January 2018

Identifiers

DOI

10.3810/PGM.2014.05.2765

1 reference

31 August 2017

1 reference